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Abstract
Background: Shoulder pain is a common musculoskeletal problem that is often chronic or recurrent. Myofascial
trigger points (MTrPs) cause shoulder pain and are prevalent in patients with shoulder pain. However, few studies
have focused on MTrP therapy. The aim of this study was to assess the effectiveness of multimodal treatment of
MTrPs in patients with chronic shoulder pain.
Methods: A single-assessor, blinded, randomized, controlled trial was conducted. The intervention group received
comprehensive treatment once weekly consisting of manual compression of the MTrPs, manual stretching of the
muscles and intermittent cold application with stretching. Patients were instructed to perform muscle-stretching
and relaxation exercises at home and received ergonomic recommendations and advice to assume and maintain
good posture. The control group remained on the waiting list for 3 months. The Disabilities of Arm, Shoulder and
Hand (DASH) questionnaire score (primary outcome), Visual Analogue Scale for Pain (VAS-P), Global Perceived Effect
(GPE) scale and the number of muscles with MTrPs were assessed at 6 and 12 weeks in the intervention group
and compared with those of a control group.
Results: Compared with the control group, the intervention group showed significant improvement (P < 0.05) on
the DASH after 12 weeks (mean difference, 7.7; 95% confidence interval (95% CI), 1.2 to 14.2), on the VAS-P1 for
current pain (mean difference, 13.8; 95% CI, 2.6 to 25.0), on the VAS-P2 for pain in the past 7 days (mean difference,
10.2; 95% CI, 0.7 to 19.7) and VAS-P3 most severe pain in the past 7 days (mean difference, 13.8; 95% CI, 0.8 to 28.4).
After 12 weeks, 55% of the patients in the intervention group reported improvement (from slightly improved to
completely recovered) versus 14% in the control group. The mean number of muscles with active MTrPs decreased
in the intervention group compared with the control group (mean difference, 2.7; 95% CI, 1.2 to 4.2).
Conclusions: The results of this study show that 12-week comprehensive treatment of MTrPs in shoulder muscles
reduces the number of muscles with active MTrPs and is effective in reducing symptoms and improving shoulder
function in patients with chronic shoulder pain.
Trial registration number: ISRCTN: ISRCTN75722066
Background
Shoulder pain is a common musculoskeletal problem. In
several countries, the 1-year prevalence is estimated to
be 20% to 50% [1,2]. The annual incidence of shoulder
pain and symptoms in Dutch primary care practice
ranges from 19 to 29.5 per 1,000 [3,4]. Shoulder pain is
the main contributor to nontraumatic upper-limb pain,
in which chronicity and recurrence of symptoms are
common [5,6]. The most common cause of shoulder
pain is considered to be subacromial impingement syn-
drome (SIS), which causes inflammation and degenera-
tion of subacromial bursae and tendons [7,8]. SIS was
first described in 1867 by French anatomist and surgeon
Jarjavay [9], was reintroduced in 1972 by Neer [10].
Although the interpretation of the physical signs during
shoulder examinations is far from reliable [11,12], the
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diagnosis of SIS is based mainly on the clinical picture
of pain in the shoulder as described by Neer [13]. The
clinical picture consists of an arc of pain, crepitus and
muscle weakness as well as a positive impingement test,
which means complete relief of pain with forced forward
elevation of the upper arm after injection of a local
anesthetic into the subacromial space [11]. Scientific evi-
dence from randomized, controlled trials (RCTs), meta-
analyses or systematic reviews of RCTs regarding the
effectiveness of multimodal rehabilitation, injection ther-
apy, medication, surgery, physical therapy or the appli-
cation of other therapies in patients with shoulder pain
is conflicting or lacking [14-24], which justifies a search
for an alternative explanation of shoulder pain, regard-
less of whether the patient is diagnosed with SIS.
A common cause of muscle pain is myofascial pain
caused by myofascial trigger points (MTrPs) [[25]; Bron
et al, unpublished work]. MTrPs in the shoulder mus-
cles produce symptoms similar to those of other
shoulder pain syndromes, including pain at rest and
with movement, sleep disturbances and pain provoca-
tion during impingement tests [26]. Clinical, histological,
biochemical and electrophysiological research has pro-
vided biological plausibility for the existence of MTrPs
[27-36]. As a result, the role of MTrPs in musculoskele-
tal pain is increasingly accepted in the medical litera-
ture. MTrPs are defined as exquisitely tender spots in
discrete taut bands of hardened muscle that produce
symptoms known as myofascial pain (Figures 1, 2, 3, 4).
MTrPs are classified into active and latent trigger
points. According to Simons et al., “An active MTrP
causes a clinical pain complaint. It is always tender,
prevents full lengthening of the muscle, weakens the
muscle, refers a patient-recognized pain on compression,
mediates a local twitch response of muscle fibers when
adequately stimulated and, when compressed within the
patient’s pain tolerance, produces referred motor phe-
nomena and often autonomic phenomena, generally in
its pain reference zone, and causes tenderness in the
pain reference zone” [[26], page 1]. Simons et al. defined
a latent MTrP as “clinically quiescent with respect to
spontaneous pain; it is painful only when palpated. A
latent MTrP may have all the other clinical characteris-
tics of an active MTrP and always has a taut band that
increases muscle tension and restricts range of motion”
[[26], page 4]. Palpation is still considered the only reli-
able clinical method of diagnosing MTrPs. Previous stu-
dies have shown that trained physical therapists can
reliably detect MTrPs by palpation [37,38]. Although
magnetic resonance elastography and ultrasound ima-
ging studies have shown potential in allowing clinicians
to visualize MTrPs, their clinical usefulness has yet to
be established [31,32].
Manual techniques, spray and stretch and trigger
point needling can inactivate MTrPs. MTrP inactivation
may be combined with ergonomic advice, active exer-
cises, postural correction and relaxation if and when
appropriate [26,39-45]. Treatment of MTrPs is rarely
included in systematic reviews of the effectiveness of
conservative interventions in patients with shoulder
pain. However, several case studies have suggested that
the treatment of MTrPs in patients with shoulder pain
may be beneficial, although well-designed controlled
Figure 1 Referred pain pattern (red) from supraspinatus
muscle MTrP.
Figure 2 Referred pain pattern (red) from infraspinatus muscle
MTrP.
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studies are still lacking [46-51]. Recently, Hains et al.
[52] compared ischemic compression of relevant MTrPs
(intervention) with ischemic compression of irrelevant
MTrPs (sham treatment). The results of this study sug-
gest that ischemic compression of MTrPs in shoulder
muscles may reduce the symptoms of patients experien-
cing chronic shoulder pain.
The aim of the current study was to assess the effec-
tiveness of a comprehensive treatment program of
MTrPs in shoulder muscles on symptoms and the func-
tioning of the shoulder in patients with chronic nontrau-
matic shoulder pain compared with a wait-and-see
approach.
Methods
A single-blinded RCT was conducted, which was
approved by the Medical Ethics Committee of the Rad-
boud University Nijmegen Medical Centre, Nijmegen,
the Netherlands [CMO 2007/022]. This RCT is regis-
tered at Current Controlled Trials [ISRCTN75722066],
and the study protocol was published previously [53].
Patients in the study sample
Between September 2007 and December 2009, all conse-
cutive patients with shoulder pain referred to a primary
care practice for physical therapy were potential study
participants. The patients were self-referred or were
referred by general practitioners, orthopedic surgeons,
neurologists or physiatrists. Patients were eligible if they
had had unilateral nontraumatic shoulder pain for at
least 6 months, were between ages 18 and 65 years and
had a clinical presentation that did not warrant referral
for further diagnostic screening. Excluded from the
study were patients who previously had been diagnosed
with shoulder instability; shoulder fractures; systemic
diseases such as rheumatoid arthritis, Reiter’s syndrome,
or diabetes; or whose medical history or physical exami-
nation suggested neurological diseases or other severe
medical or psychiatric disorders. Patients with signs and
symptoms of a primary frozen shoulder were also
excluded. Because the questionnaires were in the Dutch
language, patients had to understand written and verbal
Dutch. The lead investigator (CB) checked all available
information from referral letters and additional informa-
tion from the patients. All eligible patients were invited
to participate in the study. The patients were informed
of the study before the first assessment and signed a
written, informed consent statement.
Data assessment
Two research assistants (MO and MB; see Acknowl-
edgements), each with 30 years of clinical experience in
primary care practice and more than 5 years of experi-
ence in identifying and treating MTrPs, performed the
physical examination, including the assessment of pas-
sive range of motion (PROM) of the shoulder and the
MTrP palpation of the shoulder muscles. The total
number of shoulder muscles with active and latent
MTrPs was counted. The research assistants were
blinded to the patient treatment allocations during the
entire study period. The assessments were made at
intake, prior to randomization and at 6 and 12 weeks.
For every patient, only one observer was active. A
detailed medical history was completed, which included
demographic variables and potential prognostic factors
[54,55] and a set of self-administered questionnaires
regarding outcome measurements, including the Disabil-
ities of Arm, Shoulder and Hand (DASH) questionnaire,
Figure 3 Referred pain pattern from teres minor muscle MTrP.
Figure 4 Referred pain pattern from subscapularis muscle
MTrP. The referred pain patterns according to Simons et al. [26].
MTrPs are indicated by X. Illustrations courtesy of LifeART/MEDICLIP
[88].
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the Visual Analogue Scale for Pain (VAS-P), the RAND
Medical Outcomes Study 36-Item Short Form Health
Survey (RAND-36) and the Beck Depression Inventory,
Second Edition (BDI-II). A third research assistant (IS;
see Acknowledgements) transferred the collected data to
a worksheet. After the data from the worksheet were
transferred into the statistical software packages Systat
12, SigmaPlot 11 and SigmaStat 3.11 for Windows soft-
ware (Systat Inc., Richmond, CA, USA), the lead investi-
gator (CB), who was blinded to the patients’ treatment
allocation until all statistical tests were performed, ana-
lyzed the data. Blinding of the patients and the treating
physical therapists was impossible because of the treat-
ment characteristics.
Sample size
The planned sample size was determined on the basis of
an assumed mean improvement of the primary outcome,
a DASH questionnaire score of 15 points (SD ± 22),
which implies an effect size of 0.68 [56]. To test the null
hypothesis at a = 0.05 with 90% power and assuming a
uniform dropout rate of 5%, it was calculated that 52
patients in each group would be required.
Randomization
After collection of patients’ data at baseline, the included
patients were randomly assigned to either the intervention
group or the wait-and-see group. A research assistant (IS)
performed the randomization by generating random num-
bers using Research Randomizer software (http://www.
randomizer.org/) [57]. These numbers were stored on a
computer and were accessible only by the assistant. No
stratification or blocking strategies were used.
Interventions
The patients in the intervention group were treated by a
physical therapist once weekly for a maximum of
12 weeks. Five physical therapists were involved in the
treatment of the patients. All participating physical
therapists were experienced in treating patients with
persistent shoulder pain and MTrPs. They were trained
and skilled in the identification and treatment of MTrPs
and had successfully completed a certification-training
program in trigger point therapy.
The treatment started with inactivation of active, pain-
producing MTrPs by manual compression. The physical
therapist applied gentle, gradually increasing pressure on
the MTrP until the finger encountered a definite
increase in tissue resistance. At that point, the patient
commonly would feel a certain degree of discomfort or
pain. The pressure was maintained until the therapist
sensed relief of tension under the palpating finger or the
patient experienced a considerable decline in pain. At
that point, the therapist could repeat this procedure
several times until pressure on the MTrP would provoke
only a little discomfort without pain. This technique was
combined with other manual techniques, such as deep
stroking (pressure directed along the length of the taut
band) or strumming (pressure applied perpendicularly
across the muscle fibers). Both techniques can manually
stretch the trigger point area and the taut band. These
manual techniques could be preceded or followed by
“intermittent cold application by using ice-cubes fol-
lowed by stretching the muscle” according to Simons et
al. [26]. The effectiveness of muscle-stretching exercises
was enhanced by including short isometric contractions
and relaxation (hold-relax). Patients were instructed to
perform simple gentle static stretching and relaxation
exercises at home several times during the day. When
appropriate, the relaxation exercises were augmented by
using a portable myofeedback device (Myotrac I;
Thought Technology, Montréal, QC, Canada). Further-
more, patients were instructed to apply heat, such as a
hot shower or hot packs, for muscle relaxation and pain
relief at least twice every day. All patients received ergo-
nomic advice and instructions to assume and maintain
good posture [58,59]. The content and aim of each ses-
sion varied on the basis of the specific findings from the
initial evaluations and patients’ responses to previous
treatment sessions. All individual treatments, however,
were consistent with the limits of the treatment protocol
(Figures 5, 6, 7) [53].
Stop rule
Treatments were discontinued when patients were com-
pletely free of symptoms or when the patient and physi-
cal therapist agreed that treatment would not further
benefit the patient. Participation in the study continued
unless patients decided to stop participation in the
study. Patients were free to withdraw from the study at
any time without consequences for their treatment.
Figure 5 Manual compression on the MTrP in the infraspinatus
muscle of the left shoulder.
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Treatment integrity
To enhance the integrity of the interventions, all partici-
pating physical therapists were allowed to discuss the
content of each therapy session with the lead investiga-
tor (CB) without releasing names or any other informa-
tion that could jeopardize the blinding of the lead
investigator. After 6 and 12 weeks of treatment, the lead
investigator interviewed the patients of the intervention
group to ensure that the received treatments had been
consistent with the study protocol.
Wait and See
Patients in the control group remained on a waiting list
and were informed that they would receive the same phy-
sical therapy as the patients in the intervention group
after 3 months had passed. They were instructed not to
change the self-management of their shoulder pain. If
they were using either prescribed or over-the-counter
medication, they were encouraged to continue the
medication at their own discretion because of their parti-
cipation in the study. In addition, they were requested to
report any other intervention or other relevant change
during the study period. Every 6 weeks they visited the
physical therapy practice and provided research data
similar to the patients from the intervention group. After
12 weeks, they started physical therapy.
Outcome measures
Primary outcome measure
The Disabilities of Arm, Shoulder and Hand (DASH)
questionnaire is an internationally widely used multidi-
mensional 30-item self-report measure focusing on physi-
cal function, pain and emotional and social parameters
[60]. The score ranges from 0 to 100 whereby a higher
score indicates greater disability. The Minimal Clinically
Important Difference (MCID) is approximately a 10-point
difference between pre- and posttreatment [56,61,62]. The
DASH questionnaire is a reliable, valid questionnaire and
is considered to be one of the best questionnaires for
patients with shoulder symptoms [61,63].
Secondary outcome measures
The Visual Analogue Scale for Pain (VAS-P) is a self-
report scale consisting of a horizontal line 100 mm in
length that is anchored by the ratings “no pain” at the
left side (score 0) and “worst pain imaginable” at the
right side (score 100) [64-66]. The VAS-P was used to
measure pain at the current moment (VAS-P1), average
pain during the past 7 days (VAS-P2) and the most
severe pain during the past 7 days (VAS-P3). A 14-mm
change is considered to be a MCID in patients with
rotator cuff disease [67-70].
To assess Global Perceived Effect (GPE), the subjects
rated the effect of treatment on an ordinal 8-point scale
with categories ranging from “1 = much worse” to “8 =
completely recovered.” The GPE score was then dichot-
omized into the number of patients whose pain had
improved (from slightly improved to completely recov-
ered) versus patients whose pain had not improved
(from unchanged to much worse). The GPE scale has
good test-retest reliability and correlates well with
changes in pain and disability [71].
The PROM of the shoulder was measured using a
handheld digital inclinometer (Saunders Group Inc.,
Chaska, MN, USA) and recorded in degrees. Forward
elevation of the shoulder, external rotation and cross-
body adduction were measured in the supine position,
internal rotation in prone position and glenohumeral
abduction in the upright position. The range of motion
of the nonpainful shoulder was used as a reference. A
detailed description of the goniometric measurement of
the PROM is published in the report describing the
design of this study [53].
Figure 6 Stroking with ice (in a polystyrene cup) in
unidirectional parallel strokes combined with gentle muscle
stretching applied for the infraspinatus muscle of the left
shoulder while the patient was lying on one side.
Figure 7 Cross-body muscle-stretching exercise for posterior
shoulder muscles, including the infraspinatus muscle.
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The total number of shoulder muscles with MTrPs
was counted using the same methods as at baseline and
then compared with the baseline measurements. While
the patient was in a supine or prone position, depending
on the muscle that was examined, 17 muscles (see
appendix) were palpated bilaterally for the presence of a
taut band, spot tenderness, the presence of a nodule,
local twitch response and local and referred pain. When
the patient recognized the pain from compression on
the tender spot, the MTrPs were considered to be
active. When the pain was only local and not familiar,
MTrPs were considered to be latent [26,37,53]. At 6 and
12 weeks, participants were asked to complete a self-
assessment form, which included questions regarding
whether they had changed their self-management or had
received any medical treatment that could have influ-
enced their shoulder pain.
Statistical analysis
Analyses were performed according to the intention-to-
treat principle. Both groups were compared for baseline
characteristics using a t-test and a c2 test for binominal
variables. For the DASH, VAS-P and the number of
muscles with MTrPs, the t-test for normally distributed
data was used to assess the difference between the two
groups at week 6 and week 12. We considered a mean
difference of more than 10 points on the DASH as a
MCID. Effect sizes measured using Cohen’s d were cal-
culated to examine the average impact of the interven-
tion [72]. According to the method of Cohen, d ≈ 0.2
indicates small effect and negligible clinical importance,
d ≈ 0.5 indicates medium effect and moderate clinical
importance and d ≈ 0.8 indicates a large effect and cru-
cial clinical importance [73]. To compare patients who
improved by more than 10 points with patients who
improved by less than 10 points on the DASH question-
naire, we calculated the relative risk (RR) and the 95%
confidence interval (95% CI). To examine the impact on
individual patients in more detail, we dichotomized par-
ticipants’ measures of GPE into improved versus not
improved. The proportions of patients who had clini-
cally improved between groups were compared by calcu-
lating the RR and the 95% CI at 6 weeks and 12 weeks.
Pearson’s correlation coefficients were used to relate the
variables of number of muscles with active MTrPs and
the DASH questionnaire score.
In addition, the effect of the intervention was evalu-
ated by using regression analysis. Covariates in this mul-
tiple linear regression model were the DASH
questionnaire score at 12 weeks as the dependent vari-
able, the group variable as the DASH questionnaire
score at baseline, and the number of muscles with active
MTrPs at intake as the number of muscles with latent
MTrPs at intake, as well as the PROM.
To evaluate the success of the blinding procedure,
both observers were asked to identify the treatment
allocation. A goodness-of-fit c2 test was used to deter-
mine whether the number of correctly and incorrectly
identified cases fitted a probability of 50%. For all com-
parisons, P < 0.05 was considered statistically signifi-
cant (two-tailed). If the 95% CI of the difference did
not include the value 0, the difference was statistically
significant at a = 0.05. Systat 12, SigmaPlot 11 and
SigmaStat 3.11 for Windows software (Systat Inc.,
Richmond, CA, USA) were used for the statistical
analysis.
Results
Between September 2007 and September 2009, 72 patients
were randomly assigned to either the intervention group
or the control group. See Figure 8 for the schematic sum-
mary of patient participation and Table 1 for the patients’
characteristics at baseline. At baseline, both groups were
comparable with regard to all variables and had no statisti-
cally or clinically relevant differences, except for the num-
ber of muscles with latent MTrPs and the patients’ level of
education (Table 1).
Primary outcome measure: DASH questionnaire
The difference between the intervention group and the
control group was not significant after 6 weeks (4.1;
95% CI, -2.8 to 11.1) and was significant after 12 weeks
(7.7; 95% CI, 1.2 to 14.2). The graphic presentation of
the mean DASH questionnaire scores at intake and after
6 and 12 weeks is shown in Figure 9.
Seventeen patients (50%) in the intervention group
and seven (22%) in the control group improved by more
than 10 points (MCID) on the DASH outcome measure-
ment (RR, 2.3; 95% CI, 1.1 to 4.7) (Figure 10). The effect
size (Cohen’s d) was 0.60 (Table 2).
The multiple linear regression analysis with the base-
line score as a covariate demonstrated a significantly
higher DASH questionnaire score at 12 weeks of 7.447
(95% CI, 2.14 to 12.75) in the intervention group com-
pared with the control group. Adjustment for the cov-
ariates had no influence on this result.
Secondary outcomes
VAS-P1, VAS-P2 and VAS-P3
The intervention group showed, on average, signifi-
cantly lower scores on all VAS-P scales compared with
the control group after 12 weeks: VAS-P1 (13.8; 95%
CI, 2.6 to 25.0), VAS-P2 (10.2; 95% CI, 0.7 to 19.7)
and VAS-P3 (13.8; 95% CI, 0.8 to 28.4). The differ-
ences after 6 weeks were not significant except for
VAS-P3 (15.6; 95% CI, 2.3 to 28.8). The difference
between baseline and after 12 weeks in the interven-
tion group reached the MCID for all three VAS-P
Bron et al. BMC Medicine 2011, 9:8
http://www.biomedcentral.com/1741-7015/9/8
Page 6 of 14
scales, while changes in the control group did not
reach the MCID. The effect sizes on the three VAS-P
scales varied from 0.5 to 0.7 (Table 2).
GPE
After 6 weeks, improvement was reported by 16 (49%)
of 33 patients in the intervention group versus 5 (17%)
of 30 patients in the control group (RR, 2.9; 95% CI, 1.2
to 7.0). After 12 weeks, 18 (55%) of 33 patients in the
intervention group self-reported to be improved versus
4 (14%) of 28 patients in the control group (RR, 3.8;
95% CI, 1.46 to10.0) (Table 2).
Number of muscles with trigger points
The number of muscles with active MTrPs was signifi-
cantly lower in the intervention group than in the con-
trol group after 12 weeks (mean difference, 2.7; 95% CI,
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1.2 to 4.2). The change in the number of muscles with
latent MTrPs was nonsignificant compared with the
control group (mean difference, 0.4; 95% CI, -0.7 to 1.5)
(Table 2). The effect size (Cohen’s d) for active MTrPs
after 12 weeks was 0.89, a large effect, and for latent
MTrPs it was 0.13.
Correlation between the number of muscles with active
MTrPs and the DASH questionnaire outcome at 12 weeks
The number of shoulder muscles with active MTrPs was
positively correlated with the DASH questionnaire out-
come at 12 weeks (r = 0.49, regression coefficient = 2.13,
P = 0.000, ANOVA P = 9.6; P = 0.000, when corrected for
Table 1 Characteristics of participants at baselinea
Parameter Intervention (n = 34) Control (n = 31)
Age, mean yr (SD; 95% CI) 42.8 (11.7; 38.7-46.9) 45.0 (13.2; 40.2-49.9)
Female, number (%) 21 (62) 23 (74)
Level of educationb, number (%)
Low 2 (6) 2 (7)
Intermediate 13 (38) 17 (55)
High 19 (56) 12 (38)
Right-handed, number (%) 33 (97) 29 (94)
Pain dominant side, number (%) 24 (70) 19 (61)
Duration of complaints, number (%)
6-9 months 10 (29) 5 (16)
9-12 months 4 (12) 8 (26)
1-2 yr 8 (23) 6 (19)
2-5 yr 6 (18) 5 (16)
>5 yr 6 (18) 7 (23)
Episode, number (%)
First 13 (38) 11 (35)
Second 8 (24) 8 (26)
Third or more 13 (38) 12 (39)
DASH-DLV, mean (SD; 95% CI)c 30.3 (16.6; 24.5-36.1) 30.8 (11.9; 26.5-35.2)
VAS-P1, mean (SD; 95% CI)d 31.9 (24.3; 21.9-41.9) 35.2 (25.7; 25.7-43.0)
VAS-P2, mean (SD; 95% CI)d 41.3 (19.7; 33.2-49.4) 43.4 (17.0; 37.2-50.0)
VAS-P3, mean (SD; 95% CI)d 54.9 (21.9; 45.8-63.9) 59.5 (18.2; 52.8-66.2)
BDI-II-DLV, mean (SD; 95% CI)e 6.3 (4.0; 4.9-7.8) 5.8 (8.2; 2.8-8.8)
RAND-36-DLV, mean (SD; 95% I)f
Social functioning 78.7 (20.3; 71.6-85.8) 81.1 (18.5; 74.3-87.8)
Limitations due to physical problems 47.7 (43.0; 32.5-63.0) 49.5 (37.2; 35.8-63.1)
Vitality 59.3 (17.0; 53.3-65.1) 62.6 (17.9; 56.0-69.1)
Bodily pain 51.6 (16.0; 45.7-57.6) 52.7 (12.3; 48.2-57.2)
General health perception 52.9 (8.5; 50.0-55.9) 56.6 (7.0; 54.1-59.2)
PROM, mean (SD; 95% CI)g 28.4 (34.8; 16.1-40.7) 39.0 (34.9; 26.2-51.8)
Muscles with MTrPs, mean (95% CI)h
Active MTrPs 7.4 (3.6; 6.1-8.7) 6.1 (3.5; 4.8-7.4 )
Latent MTrPs 4.2 (2.7; 3.2-5.1) 5.9 (3.0; 4.8-7.0)
aSD, standard deviation; 95% CI, 95% confidence interval; MTrPs, myofascial trigger points. bHigh education (university and higher vocational school), medium
education (middle vocational school and higher or middle general secondary school) and low education (lower vocational school, lower general secondary school,
primary school or no education). cHigher Disabilities of the Arm, Shoulder and Hand outcome measure, Dutch-language version (DASH-DLV) scores indicate more
disability, with a maximum of 100 (range, 0-100). dHigher scores on the Visual Analogue Scale for Pain (VAS-P) indicate more pain, with a maximum of 100 (range, 0-
100). VAS-P1, current pain score; VAS-P2, average pain score for the past 7 days; VAS-P3, most severe pain score for the past 7 days. eHigher scores on the Beck
Depression Inventory, 2nd edition, Dutch-language version (BDI-II-DLV) indicate more symptoms of depression (range, 0-63). fOnly the subscales of the nine
subscales of the RAND Medical Outcomes Study 36-Item Short Form Health Survey, Dutch-language version (RAND-36-DLV) that differ significantly from a normal
Dutch population are presented here [89]. Higher scores indicate a better quality of life (range, 0-100). gA positive number (degrees) of the Passive Range of Motion
(PROM) mean score indicates impairment of the PROM of the affected shoulder. hNumber of muscles with active, respectively latent MTrPs (range, 0-17 muscles).
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muscles with active MTrPs at intake). This implies that
the number of muscles with active MTrPs was associated
with 24% of the variation in DASH questionnaire out-
come. Two cases were identified as significant outliers
during the multiple linear regression analysis (both in the
intervention group) and were removed before further
analysis.
PROM
The PROM difference between the groups did not
change significantly during the measurements at 6
weeks (mean difference, 8.8; t = 1.14; P > 0.05) and at
12 weeks (mean difference, 8.2; t = 1.19; P > 0.05).
Evaluation of blinding
After 6 weeks, the observers identified the treatment
allocation correctly in 62% of the patients (c2 = 4.70;
P = 0.03) and after 12 weeks in 71% of the patients
(c2 = 13.86; P = 0.00) after completing the physical
examination and MTrP count.
Cointerventions
We checked whether the participants in either group
had received interventions other than those described in
the treatment protocol. During the first 6 weeks of the
study, one individual in each group received an injection
administered by a general practitioner. After 6 weeks,
no cointerventions were reported in either group.
Discussion
Summary of main findings
This single-blinded RCT evaluated the effectiveness of a
12-week comprehensive MTrP physical therapy treatment
program in patients with chronic, nontraumatic, unilateral
shoulder pain when compared with a wait-and-see strat-
egy. After 12 weeks, the intervention group showed statis-
tically as well as clinically significant differences compared
with the control group on the primary and secondary out-
come measures. The effect sizes were considered to be
medium and consistent with the hypothesized effect size.
The number of shoulder muscles with active MTrPs was
significantly lower in the intervention group than in the
control group, supporting the assumed biomedical
mechanism underlying MTrP therapy.
Explaining the results and comparing them with those of
other studies
To our knowledge, this is the first study of the effective-
ness of a comprehensive MTrP therapy program in
patients with shoulder pain. The difference [74] of the
DASH questionnaire scores between groups was smaller
than the MCID. However, the mean of the baseline
DASH questionnaire score was smaller than expected
on the basis of results from other studies [56,75,76].
With a smaller mean value, observation of great differ-
ences between baseline and follow-up at 12 weeks is less
likely. However, the effect size was 0.6, which is consid-
ered to be a medium effect that is clinically relevant.
The number of patients who improved by more than
10 points in this study is a clinically relevant result.
Furthermore, many more patients in the intervention
group than in the control group reported improvement
according to the GPE scale.
Researchers in previous trials have investigated various
types of physical, manual and exercise therapy. The
treatments in these studies included interventions show-
ing similarities to components of the treatment program
of this study, but were not aimed specifically at treating
Figure 9 The mean Disability of Arm, Shoulder, and Hand
outcome measure (DASH) scores (error bars represent 95%
confidence intervals) at intake, after 6 weeks and after 12
weeks for the intervention group (n = 34) and the control
group (n = 31).
Figure 10 The number of patients who improved by more
than 10 points (minimal clinically important difference) on the
DASH outcome measure after 12 weeks for the intervention
group (n = 34) and the control group (n = 31).
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MTrPs. For example, exercise therapy or manual ther-
apy interventions included soft tissue massage and mus-
cle-stretching exercises, which generally are performed
for anterior and posterior muscle tightness [74,77-79].
These interventions may have an unintentional effect on
MTrPs in shoulder muscles because MTrPs seem to be
prevalent in patients with shoulder pain, which may
have contributed to the results of other studies [[25];
Bron et al, unpublished work]. However, because these
studies did not focus on MTrPs, there is no direct evi-
dence that these interventions did have or did not have
an effect on MTrPs.
Recently, Hains et al. [52] published the first report on
the effectiveness of ischemic compression therapy of
MTrPs in shoulder muscles in patients with chronic
shoulder conditions compared with sham compression.
The intervention group underwent 15 sessions of ther-
apy (comprising 15-second compression of MTrPs in up
to four muscles, including the supraspinatus, infraspina-
tus, deltoid and biceps) three times weekly without any
other therapeutic measures. The control group received
sham therapy (15 seconds of compression of MTrPs in
shoulder muscles, which is considered irrelevant for
shoulder pain). The intervention group showed a signifi-
cant improvement on the Shoulder Pain and Dysfunc-
tion Index compared with the sham group [52]. Hains
et al. did not report any change in the number of
MTrPs in the shoulder muscles or in the number of
shoulder muscles with MTrPs. The current study has
shown that a decrease in the number of shoulder mus-
cles with active MTrPs is correlated with better out-
come. While the number of muscles with active MTrPs
decreased in the intervention group, the number of
muscles with latent MTrPs tended to increase slightly.
One explanation might be that the state of MTrPs is
more or less dynamic and that changes from active to
Table 2 Primary and secondary outcomes in the intervention group and the control group after 6 and 12 weeksa
Outcome Intervention
(n = 34)
Control
(n = 31)
Mean difference
(95% CI)
P value Effect size
(Cohen’s d)
DASH, mean (SD)b
Baseline 30.3 (16.6) 30.8 (11.9) 0.5 (-6.7-7.7) NS
After 6 wk 23.4 (12.6) 27.5 (15.5) 4.1 (-2.8-11.1) NS
After 12 wk 18.4 (12.3) 26.1 (13.8) 7.7 (1.2-14.2) <0.05 0.60
VAS-P1, mean (SD)c
Baseline 31.9 (24.3) 35.2 (25.7) 3.3 (-9.1-15.7) NS
After 6 wk 29.0 (18.4) 37.8 (17.9) 8.8 (-0.2-17.8) NS
After 12 wk 17.2 (19.5) 31.0 (21.0) 13.8 (2.6-25.0) <0.05 0.69
VAS-P2, mean (SD)c
Baseline 41.3 (19.7) 43.4 (17.0) 2.0 (-7.1-11.1) NS
After 6 wk 32.9 (19.3) 40.0 (20.7) 6.7 (-3.6-17.0) NS
After 12 weeks 22.5 (16.4) 33.2 (23.3) 10.2 (0.7-19.7) <0.05 0.54
VAS-P3, mean (SD)c
Baseline 54.9 (21.9) 59.5 (18.2) 4.6 (-14.6-5.4) NS
After 6 wk 41.0 (25.1) 56.6 (28.3) 15.6 (2.3-28.8) <0.05
After 12 wk 34.0 (21.9) 47.8 (27.3) 13.8 (0.8-28.4) <0.05 0.57
GPE, number of patients (%) RR (95% CI)
Improved
After 6 wk 16/33 (49%) 5/30 (17%) <0.05 2.9 (1.2-7.0)
After 12 wk 18/33 (55%) 4/28 (14%) <0.05 3.8 (1.5-10.0)
Number of muscles with active trigger points, mean (SD)
Baseline 7.4 (3.7) 6.1 (3.5) 1.3 (-0.5-3.1) NS
After 6 wk 6.2 (3.5) 6.8 (3.6) 0.6 (-1.2-2.4) NS
After 12 wk 4.8 (3.0) 7.5 (3.2) 2.7 (1.2-4.2) <0.05 0.89
Number of muscles with latent trigger points, mean (SD)
Baseline 4.2 (2.7) 5.9 (3.0) 1.7 (-0.3-3.1) <0.05
After 6 wk 3.8 (2.1) 4.8 (2.8) 1.0 (-2.3-0.2) NS
After 12 wk 4.7 (2.3) 4.4 (2.3) 0.4 (-0.7-1.5) NS 0.13
a95% CI, 95% confidence interval; SD, standard deviation; ES, effect size; NS, not significant; RR, relative ratio; GPE, global perceived effect. bHigher scores on the
Disabilities of the Arm, Shoulder and Hand outcome measure, Dutch-language version (DASH-DLV) and more disability, with a maximum of 100 (range, 0-100).
cHigher scores on the Visual Analogue Scale for Pain (VAS-P) indicate more pain, with a maximum of 100 (range, 0-100). VAS-P1 represents the current pain
score, VAS-P2 represents the average pain score for the past 7 days, and VAS-P3 represents the most severe pain score for the past 7 days.
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latent and vice versa occur, depending on the degree of
irritability [80].
One of the clinical features of active MTrPs is sponta-
neous pain at rest or during activity which is felt at a
site distant from the MTrP side and, by definition, has
to be recognized by the patient as familiar pain. Accord-
ing to Mense, “The current concept of the referral of
muscle pain is based on the observation that the efficacy
of synaptic connections of central dorsal horn neurons
can change, particularly under the influence of a noci-
ceptive input. The important point is that ineffective
synaptic connections can become effective under patho-
logical circumstances. This means that a neuron can
acquire new receptive fields in the presence of nocicep-
tive input” [[81], page 350]. This process is called central
sensitization. By expanding receptive fields, non-noci-
ceptive input originating from a location other than
the originally painful location may be perceived as pain-
ful. In patients with shoulder pain, MTrPs in the infra-
spinatus, supraspinatus, teres minor or subscapularis
muscle, for example, may cause local and referred pain,
which can be felt deep within the shoulder. In other
words, MTrPs may mimic pain interpreted as pain aris-
ing from subacromial bursitis, tendonitis or tendonopa-
thy, which may explain why treatment of inflammation
is so often ineffective.
Furthermore, MTrPs can cause particular motor
effects as well. MTrPs can lead to muscle weakness of
the involved painful muscle and reorganization of motor
activation patterns. Restricted range of motion may be
observed secondary to a contracted taut band [80,82,83].
A changed motor activation pattern has often been
reported in the shoulder pain literature [84]. Since
MTrPs can alter such patterns, MTrP inactivation
should be considered prior to any form of muscle-
strengthening exercises. When muscle weakness persists,
it may alter a patient’s shoulder kinematics and even-
tually cause humeral head migration, rotator cuff degen-
eration and formation of bony spurs in the subacromial
space. Early recognition and treatment of MTrPs may
prevent the development of chronic shoulder pain and
early degeneration.
As we did not examine the effects of single compo-
nents of the intervention, we cannot conclude whether a
single component or a combination of components con-
tributed more to the treatment effect than other compo-
nents. Others have examined the effect of single
ischemic compression or a combination of ischemic
compression and stretching and concluded that both
interventions had positive effects on patients’ recovery
[44]. The management of MTrPs is not restricted to
MTrP inactivation, but it requires correction of perpetu-
ating factors that are clinically apparent but not yet
necessarily scientifically established [26,41,43]. Further
research is needed to clarify the importance of perpetu-
ating factors, such as mechanical factors, in patients
with shoulder pain [85].
Limitations of the study
The power analysis indicated that 104 patients were
needed for this clinical trial. Partly because of an overes-
timation of the number of eligible patients and partly
because of the unwillingness of patients to enter the
trial, the study was completed with a sample size smaller
than 104. This study took 2 years to complete, which is
1 year longer than originally planned. However, the
results are significant and clinically relevant, although
the study population was smaller than the initially calcu-
lated sample size. A greater sample size would be unli-
kely to have altered the direction of the results.
The participants in the intervention group had a higher
level of education than those in the control group.
Awareness of educational levels is important, as it may
affect patients’ motivation and compliance [86,87], but
adding the level of education as a covariate in multiple
linear regression analysis did not alter the results.
Evaluation of the blinding of the independent obser-
vers, who performed the physical examination and the
counting of MTrPs, revealed that after 12 weeks the
observers were able to identify to which group a patient
belonged. It is likely that the changes in physical find-
ings and the decrease in the number of MTrPs
improved the observers’ accuracy of group identification.
Since the blinding influenced only the observer who
performed the MTrP identification, this finding had no
effect on the reliability of the other outcome scores.
The patients in the control group were instructed to
maintain self-management of their shoulder pain and to
report any management deviation. While this factor may
pose a potential threat to the comparability of the
groups, no significant changes were reported. As all
patients had chronic shoulder pain and likely had
explored various self-management strategies before
entering into the study, we did not anticipate that they
would change their self-management strategies during
the study period.
Although the observers did not intend to give some
good advice during the physical examination, they may
have unintentionally instructed the patients to avoid
provocative activities. When the patients in the control
group followed the instructions and acted more carefully
during their daily lives, their symptoms may have been
reduced while they still had MTrPs. This may explain
the improvement in the control group.
Implications for research and clinical practice
This study shows that patients with chronic, unilateral,
nontraumatic shoulder pain had better outcomes after
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treatment for MTrPs than did patients without treat-
ment, and this outcome was correlated with a decrease
in the number of muscles with active MTrPs.
Treatment of MTrPs can be considered a promising
approach for the treatment of patients with shoulder
pain. Future clinical trials should be directed toward
establishing the effectiveness of MTrP treatment in
patients with varying underlying pathologies of the
shoulder and in a wider context than a specialized phy-
sical therapy practice. It would be worthwhile to identify
predictors of successful MTrP treatment and to investi-
gate whether MTrP treatment is more successful when
combined with supportive interventions such as exercise
and manual therapy. Observational follow-up studies are
needed to investigate the long-term effects of treatment
of MTrPs in patients with chronic shoulder pain. Given
the high number of patients with shoulder pain, this will
require substantial effort and financial investment. Studies
on the cost-effectiveness of treatment of patients with
MTrPs in the shoulder muscles are therefore needed.
Conclusions
Participants in the intervention group had better out-
comes on all outcome measures after 12 weeks of a
comprehensive MTrP treatment program than did those
on the waiting list. Clinically relevant improvements
were achieved in 55% of the patients with shoulder pain,
and the number of muscles with active MTrPs was sig-
nificantly decreased.
Appendix. List of muscles examined for
myofascial trigger points
Upper trapezius muscle
Middle trapezius muscle
Lower trapezius muscle
Infraspinatus muscle
Supraspinatus muscle
Subscapularis muscle
Teres minor muscle
Teres major muscle
Anterior deltoid muscle
Middle deltoid muscle
Posterior deltoid muscle
Pectoralis major muscle
Pectoralis minor muscle
Biceps brachii muscle
Triceps brachii muscle
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